Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:13:51 17/07/2025 BST			5-day change	1st Jan Change
108.96 ^USD	-0.81%		-4.81%	+18.04%

07-16	Gilead Sciences Insider Sold Shares Worth $277,575, According to a Recent SEC Filing	MT
07-16	Gilead Sciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 11:20 AM

Highlights

Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs	07-15	MT
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025	07-14	CI
ViiV expands licence to allow generic HIV treatment production for low-income countries	07-14	RE
World Health Organization recommends injectable Lenacapavir for HIV prevention	07-14	RE
Time To Grow PFL Fanbase, Revenue: CEO John Martin	07-11	MT
Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	07-10	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
Gilead finalizes agreement with global fund to accelerate access to Lenacapavir	07-09	RE
Tariff Drama, Minimal Market Reaction	07-09
Gilead Sciences, Inc. Finalizes Agreement with the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for Up to Two Million People in Primarily Low- and Lower- Middle-Income Countries	07-09	CI
Assembly Biosciences Doses First Participant in Phase 1B Portion of Phase 1A/B Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179	06-30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	06-30	RE
Gilead shares rise after US top court ruling on preventive coverage	06-27	RE
Gilead shares rise after US top court ruling on preventive coverage	06-27	RE
Assembly Biosciences Reports Positive Topline Results from Phase 1B Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B	06-25	CI
Gilead Sciences, Inc. and Kymera Therapeutics, Inc. Enter into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders	06-25	CI
Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program	06-25	MT
Global markets live: Microsoft, Gilead Sciences, Ford Motor, Vodafone, UBS…	06-19
US FDA approves Gilead's twice-yearly injection for HIV prevention	06-19	RE
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis	06-18	CI
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention	06-18	RE
Ex-dividend day	06-12	FA
US FDA pauses Gilead trials testing experimental HIV pill combination	06-10	RE
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials	06-10	MT
Gilead Says FDA Placed Clinical Hold On HIV Treatment Trials Of GS-1720 And/Or GS-4182	06-10	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 09:09 am